These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33259959)

  • 61. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
    Graham RA; Hop CE; Borin MT; Lum BL; Colburn D; Chang I; Shin YG; Malhi V; Low JA; Dresser MJ
    Br J Clin Pharmacol; 2012 Nov; 74(5):788-96. PubMed ID: 22458643
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertib.
    Lim C; Dismuke T; Malawsky D; Ramsey JD; Hwang D; Godfrey VL; Kabanov AV; Gershon TR; Sokolsky-Papkov M
    Sci Adv; 2022 Jan; 8(4):eabl5838. PubMed ID: 35080986
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.
    Maughan BL; Suzman DL; Luber B; Wang H; Glavaris S; Hughes R; Sullivan R; Harb R; Boudadi K; Paller C; Eisenberger M; Demarzo A; Ross A; Antonarakis ES
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1297-1304. PubMed ID: 27826729
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vismodegib.
    Meiss F; Andrlová H; Zeiser R
    Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer.
    Ishii A; Shigemura K; Kitagawa K; Sung SY; Chen KC; Yi-Te C; Liu MC; Fujisawa M
    Anticancer Res; 2020 Sep; 40(9):5107-5114. PubMed ID: 32878799
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vismodegib: a review.
    Ruiz-Salas V; Alegre M; López-Ferrer A; Garcés JR
    Actas Dermosifiliogr; 2014 Oct; 105(8):744-51. PubMed ID: 24359667
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.
    Bai RY; Staedtke V; Rudin CM; Bunz F; Riggins GJ
    Neuro Oncol; 2015 Apr; 17(4):545-54. PubMed ID: 25253417
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
    Yang C; Yong L; Liang C; Li Y; Ma Y; Wei F; Jiang L; Zhou H; He G; Pan X; Hai B; Wu J; Xu Y; Liu Z; Liu X
    Oncogene; 2020 Jun; 39(24):4711-4727. PubMed ID: 32404987
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
    Lyons TG; O'Kane GM; Kelly CM
    Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
    [TBL] [Abstract][Full Text] [Related]  

  • 71. P-selectin-targeted nanocarriers induce active crossing of the blood-brain barrier via caveolin-1-dependent transcytosis.
    Tylawsky DE; Kiguchi H; Vaynshteyn J; Gerwin J; Shah J; Islam T; Boyer JA; Boué DR; Snuderl M; Greenblatt MB; Shamay Y; Raju GP; Heller DA
    Nat Mater; 2023 Mar; 22(3):391-399. PubMed ID: 36864161
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phosphoproteomics of short-term hedgehog signaling in human medulloblastoma cells.
    Scheidt T; Alka O; Gonczarowska-Jorge H; Gruber W; Rathje F; Dell'Aica M; Rurik M; Kohlbacher O; Zahedi RP; Aberger F; Huber CG
    Cell Commun Signal; 2020 Jun; 18(1):99. PubMed ID: 32576205
    [TBL] [Abstract][Full Text] [Related]  

  • 73. ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice.
    Wang Q; Kumar V; Lin F; Sethi B; Coulter DW; McGuire TR; Mahato RI
    J Control Release; 2020 Jul; 323():463-474. PubMed ID: 32380205
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 75. Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells.
    Susanto E; Marin Navarro A; Zhou L; Sundström A; van Bree N; Stantic M; Moslem M; Tailor J; Rietdijk J; Zubillaga V; Hübner JM; Weishaupt H; Wolfsberger J; Alafuzoff I; Nordgren A; Magnaldo T; Siesjö P; Johnsen JI; Kool M; Tammimies K; Darabi A; Swartling FJ; Falk A; Wilhelm M
    Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20127-20138. PubMed ID: 32747535
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hedgehog-like moustache trichomegaly during treatment with vismodegib.
    Riera-Monroig J; Combalia A; Rodríguez A; Alós L; Mangas C; Ferrando J; Carrera C
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):e11-e13. PubMed ID: 31393645
    [No Abstract]   [Full Text] [Related]  

  • 77. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
    Sharma MR; Karrison TG; Kell B; Wu K; Turcich M; Geary D; Kang SP; Takebe N; Graham RA; Maitland ML; Schilsky RL; Ratain MJ; Cohen EE
    Clin Cancer Res; 2013 Jun; 19(11):3059-67. PubMed ID: 23553850
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Tang JY; Ally MS; Chanana AM; Mackay-Wiggan JM; Aszterbaum M; Lindgren JA; Ulerio G; Rezaee MR; Gildengorin G; Marji J; Clark C; Bickers DR; Epstein EH
    Lancet Oncol; 2016 Dec; 17(12):1720-1731. PubMed ID: 27838224
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
    Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
    BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.